ArticleHormone research in paediatrics2026
Efficacy and Safety of Luseogliflozin (TS-071) in Japanese Children and Adolescents with Type 2 Diabetes Mellitus: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Article in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study evaluated the efficacy and safety of luseogliflozin (TS-071), a sodium-glucose cotransporter 2 inhibitor, in Japanese children and adolescents with type 2 diabetes (T2D).
methodsIn this multicenter, randomized, double-masked, placebo-controlled phase 3 trial, patients aged 10-17 years with hemoglobin A1c (HbA1c) levels of 7.0%-12.0%, with or without prior metformin use, were enrolled. Participants were randomized (2:1) to receive luseogliflozin 2.5 mg or placebo for 12 weeks (period I), followed by a 40-week open-label extension (period II), allowing dose escalation to 5 mg.
resultsForty-eight participants were randomized and received luseogliflozin (n = 31) or placebo (n = 17). The primary endpoint - change in HbA1c from baseline at the end of period I - was -1.45% (95% CI, -1.78% to -1.11%) in the luseogliflozin group. The between-group difference in HbA1c change was -1.76% (95% CI, -2.49% to -1.02%). Luseogliflozin maintained efficacy through 52 weeks, with a mean HbA1c change of -0.92% ± 1.74% at the end of period II. Adverse events (AEs) and adverse drug reactions (ADRs) occurred in 85.4% and 29.2% of patients, respectively. No deaths occurred; three serious AEs and one mild hypoglycemic event were reported. Urinary and genital infections were the most frequent ADRs.
conclusionLuseogliflozin significantly improved glycemic control and was well tolerated, supporting its potential as an effective and safe treatment option for children and adolescents with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.